Neal D. Shore, MD

Carolina Urologic Research Center

Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center and is the Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare, US.

Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored or coauthored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy for the Large Urology Group Practice Association (LUGPA) Specialty Network. He also co-chairs the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology, and he also serves as an editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

Disclosures:

Dr. Shore has the following disclosures:
- Advisory Committee Member: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi, Tolmar
- Consultant: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi, Tolmar

Talks by Neal D. Shore, MD

The Gold Standard for Bladder Cancer Detection

Posted by Neal D. Shore, MD | Jun 2019

Neal D. Shore, MD, discusses the benefits of using blue light cystoscopy (BLC) in adjunct with white light cystoscopy (WLC) in the diagnosis and treatment of bladder cancers. He then reviews the body of evidence evaluating the accuracy of BLC in detecting significant tumors and briefly compares BLC and narrow band imaging.

29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies

Posted by Neal D. Shore, MD | Mar 2019

Neal D. Shore, MD, reviews a novel 29 MHz high-resolution micro-ultrasound system with improved visualization for prostate biopsy compared to the current standard. He also provides a brief overview of current clinical evidence for this technology.

Navigating the M0 Space- Results of RADAR III

Posted by Neal D. Shore, MD | Mar 2019

Neal D. Shore, MD, reviews the recently-published guidelines focused on next generation imaging for early detection of disease progression in M0 prostate cancer in the Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence III (RADAR III). He also reviews the goals and conclusions from RADAR I and II.

A Novel Micro-Ultrasound System for Improving Transrectal Prostate Biopsy

Posted by Neal D. Shore, MD | Nov 2018

Neal D. Shore, MD, introduces a real-time high resolution micro-ultrasound system for calculating prostate malignancy risk levels and guiding prostate biopsies. He also compares accuracy and practical benefits of micro-ultrasound to conventional ultrasound and MRI-guided biopsy techniques.

A Primer on Alternative Payment Models: The Need for a Urology APM

Posted by Neal D. Shore, MD | Apr 2018

Neal D. Shore, MD, FACS, summarizes how the Large Urology Group Practice Association (LUGPA) has and continues to preserve and advance the independent practice of urology by healthcare policy advocacy, business and administrative excellence, clinical and therapeutic education, and ensuring the success of future leaders through their Young LUGPA program.